Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTICLE-D: Proton therapy and durvalumab in unresectable NSCLC
NCT03818776Phase 1Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2019
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicities. Started Aug 2019; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03818776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818776.